| dc.contributor.author | Berlin, Jordan D. | |
| dc.date.accessioned | 2020-07-21T21:15:54Z | |
| dc.date.available | 2020-07-21T21:15:54Z | |
| dc.date.issued | 2019-08-27 | |
| dc.identifier.citation | Gorbunova V, Beck JT, Hofheinz RD, et al. Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. Br J Cancer. 2019;121(5):429-430. doi:10.1038/s41416-019-0528-0 | en_US |
| dc.identifier.issn | 0007-0920 | |
| dc.identifier.uri | http://hdl.handle.net/1803/10226 | |
| dc.description | Correction to: British Journal of Cancer (2019) 120, 183–189; 10.1038/s41416-018-0343-z; published online 11 December 2018
The original version of this article contained an error in Fig. 1a. The number of patients at risk listed in the Veliparib arm of Fig. 1a should have read “65” instead of “35”. The correct figure is below. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | British Journal of Cancer | en_US |
| dc.title | A phase 2 randomised study of veliparib plus FOLFIRI +/- bevacizumab versus placebo plus FOLFIRI +/- bevacizumab in metastatic colorectal cancer (vol 120, pg 183, 2019) | en_US |
| dc.type | Article | en_US |
